TCGA-UY-A9PA-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.909329829
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.800
- INTERFERON_GAMMA_RESPONSE+0.630
- TNFA_SIGNALING_VIA_NFKB+0.600
- TGF_BETA_SIGNALING+0.560
- PROTEIN_SECRETION+0.420
- IL6_JAK_STAT3_SIGNALING+0.410
- ESTROGEN_RESPONSE_EARLY+0.390
- P53_PATHWAY+0.390
- ALLOGRAFT_REJECTION+0.370
- APOPTOSIS+0.340
Top 10 suppressed
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- MYC_TARGETS_V2-0.310
- DNA_REPAIR-0.290
- MYC_TARGETS_V1-0.290
- SPERMATOGENESIS-0.260
- MYOGENESIS-0.200
- ANGIOGENESIS-0.180
- PANCREAS_BETA_CELLS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303760 | — | — | 0.863 |
| 2 | TCGA-K4-A6FZ-01A-11R-A31N-07 | — | — | 0.859 |
| 3 | TCGA-F7-8489-01A-31R-2403-07 | — | — | 0.859 |
| 4 | TCGA-CQ-7063-01A-11R-2403-07 | — | — | 0.855 |
| 5 | TCGA-BA-5556-01A-01R-1514-07 | — | — | 0.852 |
| 6 | SRR23036897 | — | — | 0.846 |
| 7 | TCGA-CN-6998-01A-23R-2016-07 | — | — | 0.837 |
| 8 | MNG464 | — | — | 0.833 |
| 9 | BS_S4V9E1XJ | pilocytic astrocytoma | — | 0.823 |
| 10 | SRR10900584 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.800 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.560 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.390 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.390 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| APOPTOSIS | 0.340 | Idelalisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.290 | Temsirolimus | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |